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1. Introduction
Formanydecades first-line treatment for locallyadvancedand
metastatic prostate cancer (PC) has been based on long-term
hormone therapy. The prognosis for these patients has
improved in recent years with the licensing of agents that
increase survival (docetaxel, abiraterone, enzalutamide, caba-
zitaxel, radium-223, and sipuleucel-T) and reduce morbidity
(zoledronic acid and denosumab) [1]. These agents have all
shownbenefits in the settingof castrate-resistantPC (CRPC; ie,
after first-line hormone therapy has ceased to work). More
recently, the STAMPEDE trial is assessing various treatment
approaches in the first-line, hormone naïve setting [2].
A number of randomised trials have been conducted to
assess whether men with metastatic or high-risk localised
PC starting hormone therapywould benefit from addition of
docetaxel (with orwithout other agents) [3–6]. Results from
some of the largest of these trials, including STAMPEDE [7],
have now emerged and been combined in a meta-analysis
[8]. Collectively, these studies showed that six cycles of
docetaxel extend survival and failure-free survival (FFS) for
men with metastatic PC. For men with nonmetastatic PC,
FFSwas clearly improved by docetaxel; however, therewere
relatively few deaths, so statements about overall survival
in this population remain uncertain. The National Health
Service (NHS) in England currently funds docetaxel in
newly-diagnosed men with metastatic PC who are starting
hormone therapy or who have started hormone therapy
within the last 12 wk. There is currently no NHS policy
statement regarding the use of docetaxel among patients
with high-risk nonmetastatic PC commencing hormone
therapy.
In this cost-effectiveness study, we use data from the
“docetaxel comparison”of theSTAMPEDEtrial andmodelling
methods to assess whether (1) the cost-effectiveness
evidence supports the decision made by NHS England to
fund docetaxel for patients with metastatic PC; and (2)
whether this recommendation should be extended to
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Abstract
Background: Results from large randomised controlled trials have shown that
adding docetaxel to the standard of care (SOC) for men initiating hormone therapy
for prostate cancer (PC) prolongs survival for those with metastatic disease and
prolongs failure-free survival for those without. To date there has been no formal
assessment of whether funding docetaxel in this setting represents an appropriate
use of UK National Health Service (NHS) resources.
Objective: To assess whether administering docetaxel to men with PC starting
long-term hormone therapy is cost-effective in a UK setting.
Design, setting, and participants: Wemodelled health outcomes and costs in the UK
NHS using data collected within the STAMPEDE trial, which enrolled menwith high-
risk, locally advanced metastatic or recurrent PC starting ﬁrst-line hormone therapy.
Intervention: SOCwas hormone therapy for2 yr and radiotherapy in somepatients.
Docetaxel (75mg/m2) was administered alongside SOC for six three-weekly cycles.
Outcome measurements and statistical analysis: The model generated lifetime
predictions of costs, changes in survival duration, quality-adjusted life years
(QALYs), and incremental cost-effectiveness ratios (ICERs).
Results and limitations: Themodel predicted that docetaxel would extend survival
(discounted quality-adjusted survival) by 0.89 yr (0.51) formetastatic PC and 0.78 yr
(0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER
£5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC).
Docetaxel remained cost-effective in nonmetastatic PC when the assumption of
no survival advantage was modelled.
Conclusions: Docetaxel is cost-effective among patients with nonmetastatic and
metastatic PC in a UK setting. Clinicians should consider whether the evidence is
now sufﬁciently compelling to support docetaxel use in patients with nonmeta-
static PC, as the opportunity to offer docetaxel at hormone therapy initiationwill be
missed for some patients by the time more mature survival data are available.
Patient summary: Starting docetaxel chemotherapy alongside hormone therapy
represents a good use of UK National Health Service resources for patients with
prostate cancer that is high risk or has spread to other parts of the body.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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individuals with nonmetastatic PC for whom funding is not
currently mandated in the UK.
2. Patients and methods
2.1. Overview
Themethodsforthiseconomicevaluationfollowthereferencecasesetoutby
the National Institute for Health and Care Excellence (NICE) [8] and the
reportingadheres totheConsolidatedHealthEconomicEvaluationReporting
Standards statement [9]. We used a modelling approach to predict the
lifetime experience of patients receiving each intervention. In line with the
NICE reference case, themodelusesa lifetime timehorizon, healthoutcomes
arequantiﬁed intermsasquality-adjusted lifeyears (QALYs),whichprovidea
means of reﬂecting patient morbidity and mortality, and a 3.5% annual
discount rate (the rateatwhichcostsandoutcomes incurred in the futureare
converted to their value today) is applied for costs and outcomes.
A modelling rather than within-trial analysis is necessary as approxi-
mately half of the patients in these STAMPEDE research comparisons were
still alive at the timedatawere frozen for theprimary survival analysis. Itwas
therefore necessary to account for the remainder of their projected life
experience using a predictive model (hence we use the term predicted
survival in our results). The perspective for this analysis is the UK NHS and
Personal and Social Services. Results are presented in terms of the
incremental cost-effectiveness ratio (ICER) for SOC plus docetaxel, that is,
its additional cost per QALY gained compared to SOC alone. If docetaxel
reduces costs and increases predicted QALYs, it is termed dominant.
2.2. STAMPEDE
We used the STAMPEDE trial as the main source of data to assess the cost-
effectiveness of addingdocetaxel to SOCas STAMPEDE represents the largest
trial of docetaxel in this setting, is reﬂective of UK practice, and collected
extensive data onpatient health-related quality of life (HRQoL) and resource
use. Full details of the STAMPEDE trial can be found elsewhere [2,7,10,11]. In
brief, the trial uses a multiarm, multistage (MAMS) platform design to test
whether addition of treatments at the time of long-term hormone therapy
initiation improves overall survival (OS). STAMPEDE recruitsmenwith high-
risk, locally advanced, metastatic or recurrent PC who are starting ﬁrst-line
long-term hormone therapy, and has enrolled more than 9000 men to ten
different comparisons so far [7,12]. The ﬁrst set of comparisons from
STAMPEDE revealed that docetaxel chemotherapy improved survival and
failure-free survival (FFS) but was accompanied by an increase in adverse
events. SOC-only comprised hormone therapy for at least 2 yr and
radiotherapy was encouraged for men with node-negative nonmetastatic
PC until November 2011, when it was mandated, and was optional
throughout in those with node-positive nonmetastatic disease. Docetaxel
(75mg/m2) [12] was administered alongside SOC (SOC + Doc) in six three-
weekly cycles with prednisolone 10mg daily.
2.3. Estimation of disease progression
The model structure was developed to reﬂect the natural history of PC
patients on the basis of a review of observational data, clinical guidelines,
andclinical advice (Fig.1).Apatient-level simulationapproachwasused to
generate lifetime predictions for the cohort of patients enrolled in
STAMPEDE [13]. This approach provides a simple way of reﬂecting time-
varying ratesof clinical events. Predictionswere generatedas if all patients
enrolled in the original comparisons in STAMPEDEwere allocated to SOC,
then as if all patients were allocated to SOC + Doc to eliminate chance
imbalances in patient characteristics between comparators.
A multistate survival-analytic approach was used to estimate the
rate at which individuals move through the health states in STAMPEDE
[14–16]. Parametric survival models were ﬁtted to allow extrapolation
of the estimated hazard rates beyond the data collected in the trial
period for those still alive (censored) at the preplanned analysis
[17]. The ﬁrst transition represents time to treatment failure and was
estimated as a function of treatment allocation and baseline patient
characteristics that have previously been found to be prognostic
[10,11]. Transitions beyond the point of treatment failure were
estimated conditional on patients’ treatment allocation and time of
failure. Robust data on outcomes beyond the onset of metastatic CRPC
were not available from STAMPEDE for patients with nonmetastatic PC
at baseline according to the follow-up duration currently available.
Data for metastatic CRPC cases who had metastatic disease at baseline
were therefore assumed to apply to metastatic CRPC cases with
nonmetastatic disease at baseline. This assumption was supported by
the literature [18] and clinical opinion.
2.4. HRQoL and costs
HRQoL was reﬂected in the model as a function of patients’ baseline
characteristics, the health states they occupied over time, and the toxicity
effects of docetaxel. HRQoL was estimated using the EQ-5D three-level
version (EQ-5D-3L; https://euroqol.org/eq-5d-instruments/
eq-5d-3l-about/) collected throughout follow-up for the ﬁrst 700 patients
randomised to STAMPEDE. Patient responses to the EQ-5D-3L question-
naire were converted to HRQoL weights using UK general population
preference data [19]. The resulting EQ-5D scores for all time points were
subjected to regression analysis to predict EQ-5D scores conditional on
patients’ characteristics at baseline considered to be predictive of HRQoL
according to clinical opinion (age, World Health Organisation [WHO]
status, nodal stage), chemotherapy impact, and health state, as shown in
Fig. 1. It was assumed that docetaxel toxicity impacted on HRQoL for 1 yr.
Thiswas based ondata fromSTAMPEDE that indicated that the proportion
of patients reporting worst adverse event ever as grade 3 or higher was
initially higher in the SOC + Doc group, but that this difference no longer
existed at approximately 1 yr [7]. The resulting HRQoL weights were
allocated according to patient baseline characteristics, treatment alloca-
tion, and health state to generate estimates of lifetime QALYs.
[(Fig._1)TD$FIG]
Fig. 1 – Model structure. Patients start treatment in the hormone-sensitive health state and then progress to the castrate-resistant prostate cancer
(CRPC) states. At treatment failure, patients enter the CRPC state that reflects their worst previous disease event (with the worst event being visceral
metastases, then bone metastases with history of a skeletal-related event [SRE], then bone metastases without an SRE, then CRPC with no metastases
or only lymph-node metastases). Further events can cause movement to more severe health states. Death due to prostate cancer or non–prostate
cancer is possible from any of the health states (not shown for parsimony).
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Costs were reﬂected in the model for docetaxel acquisition and
administration; adverse events; disease and toxicity monitoring; general
disease management (including hormone therapy; concomitant and
postprogression drugs, radiotherapy, and procedures; and unscheduled
primary and secondary care for PC-related hospital attendance); acquisi-
tion and administration of life-extending therapies (docetaxel, abirater-
one, enzalutamide, cabazitaxel, and radium-223); and end-of-life care
(Table 1). Resource use data were taken from STAMPEDEwhere available,
supplemented with data from the literature and clinical opinion.
General disease management costs were analysed using a regression
approach that estimated costs conditional on patient baseline char-
acteristics considered to be predictive of costs (age, WHO status, nodal
stage), whether or not the individual was within 1 yr of receiving
docetaxel, and their health state (as shown in Fig. 1). Life-extending
therapy costs were estimated for each health state and for each study
arm, as choice of life-extending therapywas found to differ substantively
between arms [7]. Monitoring costs were assumed to differ across health
states, and whether or not patients were in receipt of active therapy
requiring more intensive monitoring. Unit costs were obtained from
standard UK sources [20–23]. Generic drug costs were taken from the
electronic market information tool (eMit) [21] where possible, as these
reﬂect actual prices paid by NHS hospitals for docetaxel and other
relevant products.
An androgen-receptor pathway inhibitor (abiraterone or enzaluta-
mide) is currently the ﬁrst-line treatment choice for the majority of
patients with metastatic CRPC who receive a life-extending therapy
[24]. In STAMPEDE, these AR-pathway inhibitor treatments were used
more frequently after the onset of metastatic CRPC if patients were
allocated to SOC + Doc in the hormone-naïve setting, as part of the trial,
than if theywere allocated to SOC [7]. This reﬂects the early licensing and
reimbursement approvals of the AR pathway inhibitors. NICE approved
their use in patients who had received prior chemotherapy in 2012, and
this was extended to all patients at ﬁrst relapse in 2016 (although earlier
in England via the Cancer Drugs Fund). To reﬂect current practice, we
therefore applied the life-extending therapy usage observed in the SOC
+ Doc arm to the SOC arm and used data from the COU-AA-302 trial [25]
to model the better outcomes expected for patients allocated to SOC.
Given the limited data from STAMPEDE on life-extending therapy use in
the longer term, data were pooled across study arms and time periods
from the third year onwards for each health state.
2.5. Sensitivity analysis
Sensitivity analyses were conducted for the rates of progression through
the clinical health states, the nature of current treatment practice, and
the costs of branded and generic drugs. A probabilistic sensitivity
analysis was also conducted to jointly reﬂect all parameter uncertainty.
Results are presented separately for nonmetastatic and metastatic cases
given the differences in prognosis and long-term care.
As there is uncertainty about OS results for patients with
nonmetastatic PC given the immature data from STAMPEDE, a sensitivity
analysis was undertaken to explore the impact of inferring an OS beneﬁt
using predictive modelling from patients who had metastatic PC at
baseline. This was simulated by assigning a much higher rate of
metastases incidence to patients with nonmetastatic CRPC in the SOC
+ Doc arm. Under this scenario, gains in the SOC + Doc arm in terms of
time spent failure-free are offset by losses in time spent with CRPC.
The small group of patientswith nonregional lymphnodemetastases
as their only site(s) of metastases (M1a disease) are grouped here with
the patients with nonmetastatic PC. This is because although their
prognosis is poorer than for thosewith nonmetastatic PC, their outcomes
are closer to those for patients with advanced localised PC than to those
for individuals whose disease involved additional distant sites
[10,11]. Results were also examined by predicted time to failure to
identify any variation in cost-effectiveness according to patient
prognosis. Further details regarding the study methods and data are
provided in the Supplementary material.
3. Results
3.1. Patient prognosis over time: nonmetastatic PC
The model predicted that a higher proportion of nonmeta-
static caseswhowere allocated toSOC + Docwouldbealive at
each time point compared to SOC (Fig. 2A). These patients
spend their time predominantly without bone, bone + skele-
tal-relatedevent (SRE), or visceralmetastaseswithorwithout
treatment failure (Fig. 2B). A higher proportion of patients in
the SOC + Doc arm than in the SOC armwere predicted to be
failure-free, anda lowerproportionwerealivewith treatment
failure (Fig. 2C). Themodel predicted that docetaxel extended
unrestrictedmean survival duration by 0.78 yr (SOC 13.33 yr,
SOC + Doc 14.11 yr); extended predicted, unrestricted mean
time in the failure-free (hormone-sensitive) state by 1.42 yr
(SOC 7.08 yr, SOC + Doc 8.50 yr); and reduced predicted,
unrestricted mean time in the CRPC states by 0.61 yr (SOC
5.33 yr, SOC + Doc 4.72 yr) for the CRPC M0/M1 lymph node
state and 0.03 yr (SOC 0.92 yr, SOC + Doc 0.89 yr) for the CRPC
M1 bone, bone + SRE, or visceral states.
3.2. Patient prognosis over time: metastatic PC
A higher proportion of patients with metastatic PC who
received SOC + Doc were predicted to be alive at each time
point compared to those receiving SOC (Fig. 2D). These
patients were projected to spend their time predominantly
with metastatic disease without treatment failure or with
treatment failure and bone metastases (Fig. 2E). A higher
proportion of patients in the SOC + Doc arm than in the SOC
arm were failure-free, and a lower proportion were alive
with treatment failure (Fig. 2F). Docetaxel extended
predicted, unrestricted mean survival duration by 0.89 yr
(SOC 4.90 yr, SOC + Doc 5.79 yr); extended predicted,
unrestricted mean time in the failure-free state (hormone-
sensitive) by 0.99 yr (SOC 2.04 yr, SOC + Doc 3.03 yr); and
reduced predicted, unrestricted mean time in the CRPC M1
states by 0.10 yr (SOC 2.86 yr, SOC + Doc 2.76 yr).
3.3. HRQoL and costs
In the first year following randomisation, patients who
received docetaxel experienced a small decrement in HRQoL
(Fig. 3). Patients with CRPC have impaired HRQoL, particu-
larly those who have bonemetastases and have experienced
an SRE, and those who have visceral disease (Fig. 3). The cost
data used in themodel are shown inTable 2. Themonitoring,
management, and life-extending therapy costs are much
higher for patients with CRPC in the model.
3.4. Cost-effectiveness results: nonmetastatic PC
For patients with nonmetastatic PC, the higher costs
associated with acquiring and administering docetaxel,
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managing adverse events, andmanaging patients over their
predicted longer life expectancy were offset by lower
monitoring costs and life-extending therapy costs, as
patients would experience a shorter period of their lives
with CRPC (Table 2). The net impact of these effects is that
docetaxel is predicted to save the NHS £251 per treated
patient over patients’ lifespan. The predicted improvement
in QALYs associated with SOC + Doc was 0.39 per patient,
with patients receiving SOC + Doc accruing additional
QALYs in the failure-free state and fewer QALYs in the
CRPC states. The addition of docetaxel to SOC therefore
offers health benefits and cost savings to the NHS (ie, it is a
dominant treatment).
3.5. Cost-effectiveness results: metastatic PC
For patients with metastatic PC, the incremental costs
associated with acquiring and administering docetaxel,
managing adverse events, and managing patients over a
longer life expectancywere only partially offset by savings on
life-extending therapy costs, resulting in an incremental cost
for SOC + Doc of £2787per patient. This is because increasing
the life expectancy of patients with metastatic PC is more
costly, and because these patients experience a more similar
period with CRPC regardless of the original treatment
allocation. The predicted discounted improvement in QALYs
associatedwithSOC + Docwas0.51perpatient,withpatients
receiving SOC + Doc accruing additional QALYs in the failure-
free state and slightly fewer QALYs in the CRPC states. The
addition of docetaxel to SOC is therefore associated with an
ICER of £5514/QALY, which is considerably lower than cost-
effectiveness thresholds currentlyused in theUKNHS (which
range from £13 000 to £30 000/QALY [26,27]).
3.6. Sensitivity analyses
The results were similar across risk quartiles defined
according to predicted time to progression for both
nonmetastatic and metastatic groups. The probabilistic
sensitivity analysis indicated a very high probability (>99%)
that docetaxel is cost-effective in both nonmetastatic and
metastatic PC using the base-casemodel specifications. Two
sensitivity analyses increased the ICER above £13 000/QALY.
First, when the British National Formulary price for
docetaxel was used (which is considerably higher than
the current price the NHS pays) [20,21], the ICER for
docetaxel increased to £10 610/QALY for nonmetastatic and
£13 868/QALY for metastatic cases. When patients in the
SOC arm were assumed to be less likely to receive
abiraterone or enzalutamide in CRPC (as observed in
[(Fig._2)TD$FIG]
Fig. 2 – Predicted patient prognosis over time. (A) Overall survival for patients with M0 disease. (B) Proportion of patients with M0 disease receiving
standard of care (SOC) by health state. (C) Difference in proportion of patients with M0 disease in each health state (SOC + docetaxel (Doc) minus SOC).
(D) Overall survival for patients with M1 disease. (E) Proportion of patients with M1 disease receiving SOC by health state. (F) Difference in proportion
of patients with M1 disease in each health state (SOC + Doc minus SOC). CRPC = castrate-resistant prostate cancer; SRE = skeletal-related event,
M0 = nonmetastatic, M1 = metastatic. The grey shaded area denotes the duration of patient follow-up in STAMPEDE.
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Table 1 – Cost data used in analysis
Cost category Cost used, £ (95% CI) Source
Docetaxel acquisition, administration and monitoring costs (per course)
WHO status 0 and age <60 yr
WHO status 0 and age 60–64 yr
WHO status 0 and age 65–69 yr
WHO status 0 and age 70 yr
WHO status 1–2 and age <60 yr
WHO status 1–2 and age 60–64 yr
WHO status 1–2 and age 65–69 yr
WHO status 1–2 and age 70 yr
1897 (1777–1999)
1947 (1844–2025)
1847 (1733–1945)
1610 (1468–1738)
1422 (1044–1772)
1524 (1236–1822)
1798 (1561–2007)
1663 (1413–1873)
Analysis of STAMPEDE individual patient
data (Supplementary material)
Adverse event costs (per event)
Additional cost associated with neutropenia
Additional cost associated with febrile neutropenia
128 (NAa)
1363 (NAa)
NHS reference costs [23]
Annual cost of monitoring
Hormone-sensitive year 1
Hormone-sensitive years 2–5
Castrate-resistant
On chemotherapy, abiraterone, or enzalutamide
684 (NAb)
538 (NAb)
1764 (NAb)
2256 (NAb)
Previous studies [31], NICE appraisals [32],
expert opinion, NHS reference costs [23]
Annual costs of long-term management
Constant c
First year on SOC
First year on SOC + Doc
Age 60–64 yr
Age 65–69 yr
Age 70 yr
WHO status 1 and 2
Nodal status N+
Nodal status NX (unknown)
Health state: hormone-sensitive M1 bone
Health state: hormone-sensitive M1 visceral
Health state: CRPC M0 or M1 lymph node
Health state: CRPC M1 bone
Health state: CRPC M1 bone + SRE
Health state: CRPC M1 visceral
1209 (970–1453)
222 (107–342)
762 (524–995)
222 (479 to 38)
177 (429 to 74)
42 (289 to 369)
390 (110–663)
279 (92–456)
474 (337 to 1278)
876 (642–1123)
342 (51–661)
633 (448–799)
2295 (1978–2617)
3507 (2890–4075)
2397 (1723–3088)
Analysis of STAMPEDE individual patient
data (Supplementary material)
Annual life-extending therapy costs
Health state: hormone-sensitive M0 or M1 lymph node
Year 1
Year 2
Year 3
Health state: hormone-sensitive M1 bone
Year 1
Year 2
Year 3
Health state: hormone-sensitive M1 visceral
Year 1
Year 2
Year 3
Health state: CRPC M0 or M1 lymph node
Year 1
Year 2
Year 3
Health state: CRPC M1 bone
Year 1
Year 2
Year 3
Health state: CRPC M1 bone + SRE
Year 1
Year 2
Year 3
Health state: CRPC M1 visceral
Year 1
Year 2
Year 3
204 (7–615)
315 (7–856)
162 (55–286)
1278 (475–2141)
2469 (960–4234)
465 (213–1044)
9 (8–10)
9 (7–9)
96 (8–1567)
9831 (4894–16 010)
5226 (1020–9814)
3534 (1907–5708)
14 661 (10 914–18 671)
7488 (3875–11 599)
7344 (3758–8576)
12 861 (7774–18 112)
9120 (3888–14 899)
11 541 (5002–15 186)
7977 (1255–16 229)
24 534 (7–123,060)
3822 (7–9557)
Analysis of STAMPEDE individual patient
data
End of life (per prostate cancer-related death) 6687 (535–20 257) Round et al [33]
CI = conﬁdence interval; WHO =World Health Organisation; CRPC = castrate-resistant prostate cancer; SRE = skeletal-related event; NHS = National Health
Service; NICE = National Institute for Health and Care Excellence.
a Confidence interval not available as data represents a unit cost.
b No confidence interval available as data obtained from expert opinion and NICE guidance.
c The impact of each covariate is shown relative to a reference patient with M0 hormone-sensitive disease, not on the first year of treatment, aged <60 yr, with
WHO status 0, and node-negative disease.
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STAMPEDE), the ICER increased to £13 299/QALY for
nonmetastatic and £18 342/QALY for metastatic cases.
Inclusion of data fromameta-analysis of all relevant trials in
this area resulted in ICERs of approximately £8000/QALY for
both nonmetastatic and metastatic cases.
The sensitivity analysis to explore the impact of
assuming no survival gain in nonmetastatic PC showed
that the QALY gain was much smaller than the base-case
assumption, which predicted an OS benefit from patients
who had metastatic PC at baseline. This is because this
alternative assumption reflects only gains to patient HRQoL
(0.04 QALYs). The cost saving observed is higher (£3128)
than in the base case, as patients in the SOC + Doc arm
spend less time accruing the management, monitoring, and
life-extending therapy costs associated with CRPC. Doc-
etaxel therefore remains dominant in this scenario.
4. Discussion
We found that addition of docetaxel to SOC represents a cost-
effective use of UK NHS resources in both metastatic and
nonmetastatic PC. Further work will be reported on the cost-
effectiveness of abiraterone plus prednisolone for men
starting long-term androgen deprivation therapy following
positive survival results from STAMPEDE [28].
[(Fig._3)TD$FIG]
Fig. 3 – Impact of baseline characteristics, health state, and treatment allocation on patient health-related quality of life (HRQOL) in STAMPEDE. This
graph presents the results of an analysis of EQ-5D data obtained from STAMPEDE adjusted for baseline characteristics, treatment allocation, and
current health state. Data were collected at baseline and at follow-up visits: every 6 wk for the first 6 mo, then every 12 wk up to 2 yr, every 6 mo up
to 5 yr, and annually thereafter. The impact of each covariate on HRQOL is shown relative to a reference patient with nonmetastatic disease, World
Health Organisation class 0, age 60 yr, and node-negative in their first year of standard of care. Positive values indicate better and negative values
indicate worse HRQOL relative to the reference patient. CRPC = castrate-resistant prostate cancer; SRE = skeletal-related event, M0 = nonmetastatic,
M1 = metastatic.
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Following reports from trials evaluating the benefit of
docetaxel addition for men with metastatic or high-risk
localised PC [3,4,7,8], NHS England commissioned NICE to
review the evidence for docetaxel for patients with
metastatic PC starting long-term hormone therapy
[29,30]. On the basis of this review, NHS England concluded
that therewas sufficient evidence to support routine funding
of docetaxel for men newly diagnosed with metastatic PC
whowere starting hormone therapy or had started hormone
therapy within the last 12 wk. No evidence review or NHS
policy statement has yet been made in relation to the use of
docetaxel for patients with high-risk nonmetastatic PC
commencing hormone therapy. These economic analysis
results suggest that this position should be reconsidered.
The implications for patients with nonmetastatic PC
deserve further discussion. Given the cytotoxic nature of
docetaxel treatment,many clinicianswill require a clinically
relevant and statistically significant improvement in OS to
support its use. Unsurprisingly, at the first report of survival
data from STAMPEDE, there was not a statistically signifi-
cant improvement in OS for patients with nonmetastatic PC
(hazard ratio [HR] 0.95, 95% confidence interval [CI] 0.62–
1.47), or evidence of heterogeneity of the treatment effect
compared to metastatic PC; a meta-analysis of all random-
ised controlled trial data in non-metastatic patients showed
a trend towards improvement in OS that does not reach
statistical significance (HR 0.87, 95% CI 0.69–1.09) [8].
Our model did not use these data as the sole basis for
informing estimates of survival duration for patients with
nonmetastatic PC, as the data were considered too
immature to provide robust long-term predictions. Instead
we predicted OS by estimating the impact of treatment
failure on rates of subsequent metastases and mortality.
This approach required extrapolation of information on
outcomes in M1 CRPC from those who had metastases at
baseline to those who did not, which introduces an
additional level of uncertainty to the results, and clinicians
may be reluctant to accept a survival advantage for patients
with nonmetastatic PC until mature trial data demonstrate
this. Nonetheless, even if it is assumed that SOC + Doc does
not improve OS, our model predicts that it will result in an
increase in QALYs compared to SOC. This is because the
short-term negative effects of chemotherapy are offset by
the HRQoL benefits of delaying the onset of CRPC.
Furthermore, the cost saving on adding docetaxel is even
higher under this assumption because SOC + Doc incurs
lower costs as a result of less time spent in the CRPC state.
Hence, docetaxel remains dominant in this scenario.
The modelling was associated with other uncertainties
that are inevitable when attempting to infer the lifetime
consequences of a treatment decision from trial data, and
when attempting to predict the impact of changes to
treatment practice. These included the fact that because of
regulatory developments over the course of the trial, AR
pathway inhibitors were more frequently used after the
onset of metastatic CRPC in the hormone-naïve setting in
STAMPEDE patients allocated to SOC + Doc rather than to
SOC. The model was adjusted, using best available evidence
[24], to reflect the fact that SOC patients would now be
expected to access these treatments to the same degree.
Sensitivity analysis showed that cost-effectiveness was
somewhat dependent on this assumption, but more so in
patients with metastatic PC, as many patients with
nonmetastatic PC will die without developing M1 CRPC.
Nonetheless, our work suggests that docetaxel remains
cost-effective as long as its acquisition cost remains low,
and the AR pathway inhibitors represent the mainstay of
treatment in metastatic CRPC regardless of earlier treat-
ment choices.
The analysis adheres to the methods used for NICE
technology appraisals which are influential internationally.
Clinical, HRQoL, and resource data from STAMPEDE, and
hence the results of the cost-effectiveness analysis, are
relevant to the NHS in England. The cost of specific
resources consumed by patients may be different in other
countries, including the acquisition cost of docetaxel if NHS
hospitals are able to achieve lower prices than their
counterparts elsewhere. However, clinical practice for these
patients is similar internationally [24], suggesting that the
magnitude of benefits estimated in the analysis is likely to
Table 2 – Cost-effectiveness results
Nonmetastatic prostate cancer Metastatic prostate cancer
SOC SOC + Doc Difference SOC SOC + Doc Difference
Costs (UK pounds, discounted)
Docetaxel – 1791 1791 – 1761 1761
Monitoring 10 912 10 451 461 5471 5641 170
Management including toxicities 17 400 18 574 1174 14 415 16 555 2139
Life-extending therapies 24 679 21 964 2715 27 716 26 611 1105
End-of-life care 2124 2084 40 4864 4687 177
Total 55 114 54 863 251 52 466 55 253 2787
Life years (undiscounted) 13.33 14.11 0.78 4.90 5.79 0.89
QALYs (discounted)
Failure-free 4.44 5.27 0.83 1.40 2.02 0.63
Post-failure 3.04 2.60 0.44 1.61 1.49 0.12
Total 7.48 7.87 0.39 3.01 3.51 0.51
ICER (UK pounds/QALY) Dominant 5,514
SOC = standard of care; Doc = docetaxel; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year.
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be generalisable to other settings. Under most scenarios
considered here, we found that adding docetaxel was cost-
effective. Whether this is the case elsewherewill depend on
unit costs, including drug prices, and the cost-effectiveness
thresholds of different systems. The authors are willing to
collaborate in adapting the model for other jurisdictions.
5. Conclusions
Docetaxel is a cost-effective intervention in patients with
metastatic PC. For patients with nonmetastatic PC, our
analysis suggests that treatment is also very likely to be
cost-effective, and this is the case whether or not a survival
advantage is included. Clinicians should consider carefully
whether the evidence is now sufficiently compelling to
support initiating docetaxel in selected patients with high-
risk nonmetastatic PC currently starting hormone therapy.
Data are available for bona fide researchers on request
from the authors.
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